ArticleJournal of neuro-oncology2025
Pattern of recurrence with 1.0 cm CTV in brain glioblastoma treated with radiotherapy.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Spatial patterns of progression in reported glioblastoma cohorts after upfront chemoradiation and salvage therapy: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- Recurrence distance analysis for clinical target volume optimization in glioblastoma.Clinical and translational radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHistorically, clinical target volume (CTV) expansions for glioblastoma (GBM) have ranged from 2 to 3 cm. Since 2017, our institution has adopted a 1 cm CTV expansion beyond the gross tumor volume (GTV) and postoperative cavity on contrast-enhanced T1 Magnetic Resonance (MR) scan. Our study evaluates recurrence patterns using this approach.
methodsWe identified 50 patients who developed tumor recurrence following treatment between 01/01/2017-01/31/2024 at our institution. All patients underwent maximal safe resection followed by standard chemoradiation with 60 Gy in 30 fractions, though dose reductions to 59.4 Gy-54 Gy were permitted to meet organ-at-risk constraints. All but three patients received concurrent temozolomide. Radiotherapy target volumes were defined as follows: GTV included gross tumor and postoperative cavity on contrast-enhanced T1 MR, CTV included GTV plus a 1 cm expansion (edited for anatomical barriers), and the planning target volume included a 2 mm expansion beyond the CTV. Recurrences were classified based on the recurrence volume within the 100% isodose: in-field (> 80%), marginal (20-80%), and distant (< 20%).
resultsRecurrence patterns were as follows: 80% (40/50) in-field alone, 10% (5/50) in-field and distant, 8% (4/50) distant alone, and 2% (1/50) marginal alone. The single marginal recurrence had 52% of its volume within the 100% isodose.
conclusionsIn GBM patients treated with a 1 cm CTV margin on the gross tumor and postoperative cavity on contrast-enhanced T1 MR, we observed a very low marginal recurrence (2%). These findings support the continued use of a 1 cm CTV expansion at our institution.
Indexed as
Identifiers
40788565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.